Advertisement

Going Virtual in the European Biopharmaceutical Industry: Conductors and Oxpeckers Make It

  • Valérie Sabatier
  • Vincent Mangematin
  • Tristan Rousselle
Part of the IFIP – The International Federation for Information Processing book series (IFIPAICT, volume 283)

In the sector of biopharmaceuticals, the dominant business model remains the one of big pharmas: the vertical integration. However we currently observe in the European biotechnology industry the emergence of new business models. This article studies in particular the cases of an orchestra firm and a repurposing firm, both virtual all along the value chain of drugs.

It shows that being virtual is possible in the European biopharmaceutical industry. Small virtual firms are able to play the role of hub firms in networks. These organizations, despite their small size and limited funding, manage to build networks with academics and industrials, long-run partnerships, and, icing on the cake: the drug development cost should be much lower than big pharmas’.

Keywords

Business Model Venture Capitalist Chief Financial Officer Strategic Partner Biotech Firm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© International Federation for Information Processing 2008

Authors and Affiliations

  • Valérie Sabatier
    • 1
    • 4
  • Vincent Mangematin
    • 1
    • 2
    • 3
  • Tristan Rousselle
    • 4
  1. 1.UMR 1215 GAELUniv. Grenoble 2GrenobleFrance
  2. 2.UMR 1215 GAELINRAGrenobleFrance
  3. 3.Grenoble Ecole de ManagementGrenobleFrance
  4. 4.Protein’ eXpertGrenobleFrance

Personalised recommendations